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Electroconvulsive therapy is known to be effective in the treatment of mood disorders, more specifically for depression and
mania. Although a large body of evidence confirms the efficacy of electroconvulsive therapy in the treatment of mania, few prospective
studies have been done to assess its effectiveness in treatment-resistant manic episodes. These case reports describe the initial
results of a study that is being conducted to evaluate the efficacy of Electroconvulsive therapy among treatment-resistant bipolar
patients.
METHODS: Three manic patients (according to DSM-IV criteria) who were considered treatment-resistant underwent a
series of 12 bilateral Electroconvulsive therapy sessions. Before the treatment and then weekly, they were evaluated with the following
rating scales: Young Mania Rating Scale, Hamilton Rating Scale for Depression, Brief Psychiatric Rating Scale, and Clinical Global
Impressions—Bipolar Version.
RESULTS: The 3 patients showed a satisfactory response to Electroconvulsive therapy, although some differences in the
course of response were observed.
CONCLUSION: These case reports suggest that Electroconvulsive therapy needs further evaluation for the treatment of
resistant bipolar patients.
DESCRIPTORS: Bipolar mood disorder. Mania. Treatment. Drug resistance. Electroconvulsive therapy.
From the Mood Disorders Unit (GRUDA),
Psiquiatric Institute, Hospital das Clínicas,
Faculty of Medicine, University of São Paulo.
For more than 60 years, since its in-
troduction in the management of psy-
chiatric disorders by Cerletti and Bini
in 1938, Electroconvulsive therapy
(ECT), although more frequently re-
lated to the management of resistant
depression, has also been associated
with the successful treatment of manic
episodes. Actually, mania is considered
the third most common indication for
ECT in psychiatric practice1,2.
Mukherjee et al.3, in an excellent
review, reported the response rates of
ECT in the treatment of mania de-
scribed by different studies between
1942 and 1992. The 15 studies re-
viewed included a total of 589 patients,
80% of them showing remission or
marked clinical improvement.
Between 1942 and 1959, seven
studies that included at least 20 patients
each found a significant clinical im-
provement in 78% of the 400 manic
patients evaluated3. In those studies,
however, resistance to treatment was
not a selection criterion, since the phar-
macological approach to psychiatric
disorders was in its infancy, and
lithium was first introduced in the
1950s.
Another 6 studies using a retrospec-
tive design with a total of 150 patients
were performed between 1976 and
1992. ECT-induced remission or clini-
cally marked improvement was found
in 85% of the 150 manic patients stud-
ied, but treatment resistance was not
considered as a criterion for the pa-
tients’ selection3. Some of these retro-
spective studies matched patients by
sex and age and compared the response
rates of manic patients treated with
ECT (before the introduction of phar-
macotherapy) and chlorpromazine;
they concluded that ECT was an effec-
tive treatment, as compared to no treat-
ment, including for those patients with
no clinical response to chlorpro-
mazine4,5. Thomas and Reddy6 com-
pared ECT, chlorpromazine, and
lithium in the treatment of manic pa-
tients and could not find differences
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among the 3 groups. Alexander et al.7
and Strömgren8 studied the response to
ECT among patients not responsive to
pharmacotherapy (without specifying
the criteria for treatment resistance)
and found that 56% and 59% of the
patients, respectively, showed a good
response to ECT after failed pharma-
cotherapy.
Two prospective studies performed
by Small et al.9 and Mukherjee et al.10,
which included a total of 39 patients,
aimed at assessing the effectiveness of
ECT for treating mania. Small et al.9
compared the efficacy of lithium and
ECT. The patients in the ECT group had
not shown a satisfactory response to pre-
vious treatments, which were not de-
scribed. Of the 17 patients referred for
ECT, total or partial remission was ob-
served in 100%, and the authors con-
cluded that lithium and ECT were
equivalent in their efficacy. Among pa-
tients with severe mania, however, ECT
proved to be superior to lithium9.
Mukerjee et al.11 studied the efficacy of
ECT and haloperidol plus lithium in
manic patients who did not show a good
previous response to neuroleptics or
lithium. Remission was defined as when
the patients did not meet criteria for
mania or hypomania according to the
Research Diagnostic Criteria (RDC)12.
ECT was effective in 59% of 22 pa-
tients, but for some nonresponders, a
worsening of the clinical picture was
observed11. Of the 39 manic patients in-
cluded in both studies, ECT was effec-
tive in 77%.
Schnur et al.13 studied the response
rates of ECT among treatment-resistant
manic patients in a study that also aimed
to identify possible predictive factors of
nonresponse among these patients. The
patients included in the study—selected
using the criterion of treatment resist-
ance—had been treated with lithium,
(blood levels between 1.0 and 1.5 mEq/
L), or neuroleptics (dosages equivalent
to 1500 mg/day of chlorpromazine) for
3 weeks, without clinical response. They
underwent an average of 9 daily bilat-
eral sessions of ECT. Sixty-six percent
of the patients showed a good response
to ECT. Among nonresponders, the au-
thors13 identified some clinical charac-
teristics such as anger, irritability, and
suspiciousness.
There are large differences among
these studies. The diagnostic criteria
adopted in the patients’ selection and the
methodology employed (for example,
retrospective versus prospective designs,
absence of a control group in some
studies, and criteria of remission and
clinical improvement) were different,
but ECT was unequivocally associated
with successful treatment of mania.
We present preliminary cases of a
study designed to evaluate the efficacy
of ECT in bipolar pharmacotherapy-
resistant patients.
METHODS
The patients were referred for ECT
after being considered treatment-resist-
ant according to the following criteria:
(1) Bipolar mood disorder (BP):
manic, mixed or depressive episode,
according to the Structured Clinical In-
terview Diagnostic—SCID (version
2.0, 8/98)14 that follows the criteria of
the Diagnostic and Statistical Manual
of Mental Disorders, 4th edition—
DSM-IV15. (2) Treatment-resistant ma-
nia: manic episode not responsive to at
least 2 anti-manic treatments (for ex-
ample, 1 mood stabilizer and 1 neu-
roleptic or combinations of mood sta-
bilizers) in adequate dosages for 6
weeks (blood levels of lithium between
0.8 and 1.2 mEq/L, carbamazepine be-
tween 8 and 12 µg/mL, valproic acid
between 45 and 125 µg/mL, and neuro-
leptics in doses equivalent to 5-20 mg/
day of haloperidol). An additional in-
clusion criterion was a Young Mania
Rating Scale (YMRS) total greater than
1616. (3) Treatment-resistant bipolar
depression: depressive episode not re-
sponsive to at least 2 trials with anti-
depressants for 8 weeks in adequate
dosage regimens, in association with a
mood stabilizer, also with adequate
blood levels as described above for
lithium, carbamazepine, and valproic
acid. Antidepressant dosage regimens
were considered adequate when they
were equivalent to 60 mg/day or maxi-
mum tolerated dose of fluoxetine or 80
mg/day or maximum tolerated dose of
tranylcypromine. As an additional cri-
terion, a total score of 18 was required
on the Hamilton Rating Scale for De-
pression (HAMD-21, 21 items)17.
After the informed consent was
signed, routine laboratory tests (total
blood cell count, serum electrolyte lev-
els, urinalysis, glycemia, blood urea
and creatinine, thyroid screening tests,
chest x-ray, electroencephalogram, and
a computed tomography (CT) scan of
the brain), were performed. The pa-
tients also underwent cardiac, odonto-
logical, and neurological evaluations to
identify possible clinical conditions
that would counterindicate ECT. These
are necessary procedures for every pa-
tient referred for ECT, according to the
Biological Treatment Unit–ECT of the
Institute of Psychiatry–HCFMUSP18.
The current medication was withdrawn
by 50% on the first day, and by 25%
on the following days until total dis-
continuation.
After 1 week of washout, the pa-
tients underwent 12 sessions of bilat-
eral ECT in a 3-times-a-week schedule
under anesthesia with atropine (0.4 to
1.0 mg/kg) and etomidate (0.2 to 0.3
mg/kg, or in case of intolerance,
propofol, 2 to 2.5 mg/kg) and muscle
relaxation with suxamethonium chlo-
ride (0.6 mg/kg). The ECT device used
in the study was a Thymatron (TM)
DGx, which offers a brief-pulse square
wave delivered with a constant current
of 0.9 A. The electrically induced
seizure was considered adequate when
its duration was greater than 20 sec-
onds.
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Before and after the washout week,
as well as weekly during the 12 ECT
sessions (after the 3rd, 6th, 9th and 12th
session), the patients were evaluated
with the following scales: YMRS16,
HAMD-2117, Brief Psychiatric Rating
Scale (BPRS)19, and Clinical Global
Impressions—Bipolar Version (CGI-
BP)20.
Clinical response was considered to
be at least a 50% reduction in the
YMRS and HAMD-21 scores, with fi-
nal scores of the YMRS lower than 12
and HAMD-21 lower than 8.
RESULTS
Case No 1
Male, 29 years old, separated, 2
daughters. Family history of general-
ized anxiety disorder and major de-
pression (sister). First episode at age
21, with psychotic symptoms, when he
was diagnosed as schizophrenic. Dur-
ing this episode, he received ECT with
good response (number of treatments
and electrode placement not available).
At age 26, he was hospitalized again
for 3 months and received neuroleptics
(haloperidol and chlorpromazine, dos-
age regimens not available). The next
year after his brother’s death, he devel-
oped a period of agitation, insomnia,
and hyperactivity lasting 1½ months.
Hospitalization was not necessary,
since he improved with neuroleptic
treatment. The third and fourth hospita-
lizations occurred because of episodes
of extreme psychomotor agitation, in-
somnia, mystical and persecutory de-
lusions, and auto- and hetero-aggres-
sive behavior that lasted an average of
3 months. After the fourth hospitaliza-
tion, he started maintenance treatment
with haloperidol (average dose of 10
mg/day), and 1 year later had a mild
episode of agitation and increased ac-
tivity for 1 month. The fifth hospitali-
zation 1 year later lasted 6 months be-
cause of a severe episode of 10 months
duration. He showed the same charac-
teristics described above, attempted
suicide, and was diagnosed as bipolar,
manic, with psychotic symptoms.
Treatment with lithium was started,
with blood levels maintained between
0.8 and 0.9 mEq/L. The first depressive
episode broke up 8 months later, and
after a week receiving sertraline 50 mg/
day in association with lithium, he
switched to mania. Haloperidol was
then introduced at 15 mg/day after the
interruption of the antidepressant;
lithium was maintained at 1350 mg/
day (blood level at 0.9 mg/day), and
after 6 weeks, carbamazepine (600 mg/
day) was introduced. After 10 weeks
with no adequate response, he was re-
ferred for ECT.
According to the SCID, the diagno-
sis was current manic episode with
mood-incongruent psychotic symptoms,
and as additional conditions, past alco-
hol and cocaine abuse. Relatives re-
ported that the patient always increased
alcohol consumption and started co-
caine abuse after the worsening of the
affective symptoms. All laboratory tests
cited above were within the normal
range. Clinical and neurological evalu-
ations did not show a pathological con-
dition. The initial and subsequent scores
of the rating scales are described in fig-
ure 1. (Table 1).
Case No 2
Male, 50 years old, divorced, no
children. Family history of bipolar dis-
order (BP) (sister confirmed, brother,
father, and grandmother suspected) and
alcohol and cocaine abuse (brother and
uncle). First episode at age 30, with
manic symptoms. History of 19 manic
and 8 depressive episodes (shorter and
milder than the manias) and 10 hospi-
talizations, all for mania. Comorbidity
of AIDS, diagnosed 7 years previously.
It is not clear whether his contamination
was after a blood transfusion during a
treatment for malaria or was a conse-
quence of promiscuity coincident with
a manic episode. During the first 6
years, he had a frequency of 1 manic
episode every year. After 1987, how-
ever, when he first manifested depres-
sive symptoms for 1 month, the fre-
quency of the episodes increased, with
an average of 2-3 per year. At that time,
he was taking lithium (1500-2400 mg/
day) with neuroleptics (haloperidol, 3-
15 mg/day, or trifluoperazine, 5-15 mg/
day) added as needed for the treatment
of manic episodes, as well as antide-
pressants for depressive episodes (imi-
Table 1 - Initial and subsequent total scores of the rating scales – Case No 1.
initial After washout Week 1 Week 2 Week 3 Week 4
HAMD-21 15 15 15 12 6 5
YMRS 43 53 52 32 12 3
BPRS 56 61 61 51 25 24
CGI-BP (GLOBAL) 7 7 7 6 4 2
Figure 1 - Initial and subsequent total scores of the rating scales – Case No 1.
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pramine, 50-200 mg/day, when he
switched to mania, and moclobemide,
200-400 mg/day). After a manic episode
at the beginning of 1993, the mainte-
nance treatment included lithium and
neuroleptics. For almost 2 years, the pa-
tient remained relatively well, when a
new hypomanic episode erupted at the
end of 1994. During 1995, the patient
remained in mania/hypomania for 9
months, with brief euthymic periods,
and remained almost 8 months at the
hospital. At that time, he had some clini-
cal complications, such as 2 instances of
possible lithium intoxication, worsening
of the renal function, and diabetes insip-
idus. After many discontinuations,
lithium was maintained at 600 mg/day
(blood levels around 0.6 mEq/L),
carbamazepine was added (reaching
1600 mg/day, blood levels 8-10 µg/mL),
and neuroleptics were maintained (ha-
loperidol, 2.5 to 7.5 mg/day; rispe-
ridone, 6 to 10 mg/day, in association
at the beginning; risperidone on an av-
erage of 8 mg/day thereafter). The next
year, he had only 2 questionable peri-
ods of hypomania and a mild depression
for 1 month (citalopram was introduced
at 20 mg/day and maintained for 4
months; neuroleptics were withdrawn).
He developed diplopia as a side effect,
and carbamazepine was reduced to
1000 mg/day, with resolution of the
symptoms. Irritability remained a con-
stant complaint and clinical symptom.
At the beginning of 1997, he was again
hypomanic. Valproate was introduced
in substitution for carbamazepine, in-
creased up to 2000 mg/day (blood lev-
els, 59 µg/mL), lithium was increased
up to 750 mg/day, and clonazepam was
added up to 9 mg/day, but he remained
irritable, more talkative, with question-
able plans for almost the entire year. In
November 1997, a new depressive epi-
sode was treated with citalopram, 20
mg/day, for 4 months, valproate was
maintained at 2000 mg/day, and
lithium was increased up to 1050 mg/
day. He remained well for 6 months.
Routine laboratory evaluations re-
vealed elevated TSH levels (5.3 mUI/
mL), leading to levothyroxine replace-
ment up to 50 µg/day. He developed a
new manic episode in June 1998, when
valproate was increased up to 3000
mg/day; risperidone, 4 mg/day, was
added, but lithium had to be reduced
to 600 mg/day because of the worsen-
ing of polyuria. He developed nausea
and vomiting, and valproate had to be
reduced to 1750 mg/day. A milder
manic episode developed again and
improved after the elevation of the
risperidone (1 to 2 mg/day), and hyper-
metabolic administration of thyroxin
was tried (150 µg/day). He remained
well for 2 months, but again manic
symptoms arose. Risperidone was in-
creased to 4 mg/day; valproate was
changed for lamotrigine, reaching
75 mg/day.
He was referred for ECT after a
trial of lithium 600 mg/day (blood lev-
els, 0.9 mEq/L), lamotrigine, 75 mg/
day; risperidone, 4 mg/day; and clona-
zepam, 2 mg/day, without improve-
ment of the manic symptoms for al-
most 8 weeks. Concurrent medication
was indinavir, 2400 mg/day; stavudine,
80 mg/day; Epivir, 300 mg/day; and
sodium levothyroxine, 150 µg/day, for
the management of lithium-induced
hypothyroidism.
According to the SCID, the diagno-
sis was current manic episode without
psychotic symptoms with comorbidity
of AIDS and subclinical hypothy-
roidism. Laboratory tests were normal,
including TSH, 1.2 mUI/mL; free T4,
1.5 mUI/mL; CD4, 419; and CD4/CD8,
0.31. No tomographic abnormalities
were observed. The neurological and
clinical evaluations were normal. Psy-
chiatric medication was withdrawn at
the rate described for case 1, and the
anti-retroviral drugs and l-thyroxin were
maintained during the series of ECT
procedures. Occasionally, promethaz-
ine, 25 mg P.O., was administered be-
cause of insomnia. The initial and sub-
sequent scores of the rating scales are
described in figure 2. (Table 2).
Case No 3
Female, 41 years old, divorced, 2
children. No family history of BP. First
episode at age 26, in the 2nd puerper-
ium, diagnosed as puerperal psychosis
and treated with amitriptyline, 225 mg/
day, and diazepam, 10 to 20 mg/day.
She switched to mania and started tak-
ing lithium (900 to 1050 mg/day;
Table 2 - Initial and subsequent total scores of the rating scales – Case No 2.
initial After washout Week 1 Week 2 Week 3 Week 4
HAM-D 14 12 6 6 4 3
YMRS 40 32 14 18 12 2
BPRS 47 40 30 30 30 23
CGI-BP (GLOBAL) 6 6 4 4 4 2
Figure 2 - Initial and subsequent total scores of the rating scales – Case No 2.
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blood levels, 0.7 mEq/L) and haloperi-
dol (15 mg/day). Two months later, she
switched to depression. For 2 years she
lived in another country, and relatives
reported that she was treated with ECT
and neuroleptics without mood stabi-
lizers, probably because of another
manic episode (no details regarding
ECT and neuroleptic treatments could
be obtained). Back in Brazil, she be-
came depressed and started taking am-
itriptyline, 75 mg/day, for 1 month,
switching to mania. A third hospitali-
zation was needed because of the se-
verity of the episode and the presence
of psychotic symptoms. Chlorpro-
mazine, 400 mg/day, was given for 1
month, and lithium was restored reach-
ing 1200 mg/day (blood levels, 1.0
mEq/L). After 2 months of euthymia,
a new depressive episode led to the in-
troduction of tranylcypromine, 10-20
mg/day. TSH levels were increased
(39.5 mUI/mL), and l-thyroxin, 150
µg/day, was added (TSH was 1.2 mUI/
mL after 3 months). Almost 1 year
later, a new mild and brief depressive
episode was treated with fluoxetine, 20
mg/day, with the patient remitting in 1
month. The patient remained euthymic
for the next 18 months, but she stopped
taking medication in order to “lose
weight”. A new depressive episode oc-
curred, and the patient switched again
to mania after 1 month of lithium, 900
mg/day; tranylcypromine, 10 mg/day;
and l-thyroxin, 150 µg/day. The fourth
hospitalization lasted 2 months. She
was then maintained on lithium, but
thyroid supplementation was inter-
rupted (reason not described). Five
months later, she was hospitalized for
3 months in a psychotic manic episode.
Subsequently, the first mixed episode
was suspected. Lithium was main-
tained (1200 mg/day, blood levels be-
tween 0.8 and 1.0 mEq/L); risperidone,
2 mg/day (for 1 month), and clona-
zepam, 2 mg/day, were added. A new
thyroid screening revealed increased
TSH levels in May 1994, and therapy
with l-thyroxin was restored at 50 µg/
day. Three months later, after taking
the medication in an irregular way, a
new manic episode with psychotic
symptoms occurred. After being hos-
pitalized for 2 months (lithium was
maintained, carbamazepine was intro-
duced and increased to 500 mg/day,
and haloperidol was introduced and
maintained for 2 months), she was dis-
charged, but 1 month later needed to
be hospitalized again in the second
possible mixed episode. Carbama-
zepine was increased to 1000 mg/day
and lithium to 1500 mg/day (blood lev-
els, 1.2 mEq/L), and haloperidol was
restarted at 5 mg/day. After 3 months,
she left the hospital, but a possible mild
mixed episode was monitored for 7
months. With the resolution of the
symptoms, she remained well for al-
most 1 year, receiving lithium, 1350
mg/day (mean blood level, 0.8 mEq/
L); carbamazepine, 1200 mg/day
(mean blood level, 10 µg/mL); and l-
thyroxin, 100 µg/day. A mild hy-
pomanic episode developed, but the in-
stitution of clonazepam at 2 mg/day
apparently stopped the symptoms. The
next winter, she had a moderate de-
pressive episode and took moclo-
bemide for almost 9 months (3 months
at 450 mg/day, 3 months at 900 mg/
day, 2 months at 750 mg/day and 1
month at 300 mg/day). There was a
suspicion of lithium toxicity, which led
to the reduction of the lithium dose to
900 mg/day, which was increased to
1200 mg/day. Even with the reduction
in the antidepressant dosage she had a
mild switch to mania. Three months
later, she was again hospitalized in a
more characteristic mixed episode,
when carbamazepine was discontin-
ued, and valproate was introduced and
increased to 2000 mg/day (blood lev-
els, 100 µg/mL). Since she also devel-
oped psychotic symptoms, risperidone
was added (4 mg/day, then reduced to
2 mg/day). During the mixed episode,
l-thyroxin was increased to 150 µg/day.
Because of a suspected mild intoxica-
tion, lithium was reduced to 600 mg/
day. One year later, with a maintenance
treatment with valproate, 1000 mg/day
(reduced because of the development
of cutaneous rash); lithium, 750 mg/
day; and l-thyroxin, 150 µg/day, she
was mildly depressed. Tranylcypro-
mine, 10 mg/day, was added. The pa-
tient again developed a mixed episode
with psychotic symptoms and was then
hospitalized for the ninth time.
According to the SCID, the diagno-
sis was current mixed episode with
psychotic symptoms with comorbidity
of asthma, obesity, and subclinical hy-
pothyroidism. When she was referred
for ECT, she was on lithium, 1200 mg/
day (blood levels, 0.7 mEq/L with 900
mg/day); valproate, 2000 mg/day
(blood levels, 49 µg/day with 1000 mg/
day); risperidone, 4 mg/day; and l-thy-
roxin, 150 µg/day. Lithium and val-
proate were discontinued, and since
she remained agitated and the psy-
chotic symptoms increased after the
washout period, risperidone was main-
tained at 2 mg/day until the 5th admin-
istration of ECT. The initial and sub-
sequent scores on the rating scales are
described in figure 3. (Table 3).
DISCUSSION
The initial HAMD-21 scores rated
in case 1 represented the items insom-
nia, agitation, paranoid symptoms, and
insight, which are actually manic
symptoms. After the washout period,
there had been a worsening of the clini-
cal picture as was also evidenced by
the rating scales. Concurrent medica-
tion was needed because of the ex-
treme psychomotor agitation, aggres-
sive behavior, and risks for the patient
(self-injury, injury of other patients).
During the weeks 1, 2, and 3, he re-
ceived an average of 10 mg haloperi-
dol/day I.M. and short half-life benzo-
diazepine (midazolam 15 mg P.O.) for
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insomnia as needed. After the 9th ECT
session, he showed improvement ac-
cording to the clinical evaluations and
rating scales, and the medication was
discontinued. After 12 ECT sessions
(all effective), he remitted. Mild head-
ache was the only reported side effect
mainly after the ECT sessions, and
these always remitted with dipyrone,
30 gtt P.O.
Some authors9,13 report that a sig-
nificant clinical response of manic epi-
sodes may be evident only after the 9th
administration of bilateral ECT. Schnur
et al.13 suggested that the presence of
symptoms like suspiciousness, irritabil-
ity, and anger might contribute to a
poorer response to ECT. The rapid
withdrawal of lithium may also have
contributed to the worsening of the
manic symptoms after the washout
week21. A particular difficulty observed
in the management of the patient was
the maintenance of a 3-times-a-week
schedule, sometimes because of na-
tional holidays (when the ECT unit is
closed), and other times because it was
difficult to sustain the fasting as re-
quested. This reinforces the importance
of keeping a rigorous schedule for
these patients.
In case 2, the HAMD-21 scores re-
lated to insomnia, agitation, psychic
and somatic anxiety, and insight, which
also related to the manic symptoms, as
in case 1. In this case, it is noteworthy
that after the washout period, a reduc-
tion in the scores was observed. One
reason could be that AIDS patients
(and more frequently those with AIDS
dementia) are more sensitive to poly-
pharmacy, especially to side effects,
and prone to develop delirium with
psychomotor agitation and behavioral
changes22,23. Treisman et al. 23 sug-
gested that the use of lithium in AIDS
patients could be complicated because
of the high rates of associated delirium
and toxicity, and because of fluctuation
of blood levels. This possibility could
be speculated for this case, although no
impairment of consciousness was ob-
served, and the electroencephalogram,
computer tomography, and neurologi-
cal evaluation did not show a patho-
logical condition at admission. How-
ever, normal CT images can be ob-
tained in the initial stages of AIDS de-
mentia22. Although lamotrigine has
been successfully used in AIDS pa-
tients, there are reports of some mood
elevating properties, and this should be
taken into account in this case23. After
the initial reduction, an elevation of
YMRS scores was observed. This el-
evation could be explained by the pro-
longed interval between weeks 1 and
2, and even by the patient’s associated
clinical condition (he developed a uri-
nary infection and fever, which con-
tributed to the cancellation of one ECT
session). There might also have been a
worsening of the manic episode during
the ECT course as described by
Mukherjee et al.10 and Schnur et al.13.
As also seen in case 1, the response
was more evident after the 9th ECT; af-
ter the 12th ECT, the patient was con-
sidered remitted according to the clini-
cal evaluation and the rating scales. In
the literature, there are also reports of
successful treatments of depressive epi-
sodes and stupor among serum-positive
and AIDS patients with ECT24,25. Mod-
erate headache and nausea were fre-
quently reported after the ECT ses-
sions, but stopped after treatment with
dipyrone, 30 gtt P.O. Memory impair-
ment was the most important com-
plaint during the 3 weeks that followed
the ECT course, but it later improved.
Differently from the others dis-
cussed above, the HAMD-21 items
scored in case 3 represented symptoms
such as depressive mood, guilt feel-
ings, agitation, psychic and somatic
anxiety, mood variation, and paranoid
symptoms. There are no controlled
studies designed to assess the efficacy
of ECT in mixed states. Case reports
and naturalistic studies suggest that
ECT is a good treatment option for
these patients, who are less responsive
to lithium, but who show an adequate
response to anticonvulsants, especially
to valproate26. Dilsaver et al.27 reported
recovery among 7 patients with depres-
sive mania treated with ECT. The pres-
ence of depressive symptoms could
explain the faster response to ECT,
with a good clinical improvement ob-
served after the 6th administration, as
already described by other authors9,13.
Table 3 - Initial and subsequent total scores of the rating scales – Case No 3.
initial After washout Week 1 Week 2 Week 3 Week 4
HAM-D 21 22 17 10 10 6
YMRS 25 31 12 5 1 1
BPRS 40 51 39 24 25 23
CGI-BP(global) 6 6 5 4 3 2
Figure 3 - Initial and subsequent total scores of the rating scales – Case No 3.
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Small et al.9 reported indeed that the
presence of depressive symptoms was
the strongest predictor of good re-
sponse to ECT. Even with the faster re-
sponse and greater initial reduction in
the YMRS total values, the depressive
symptoms remained until the 12th ECT.
The final HAMD-21 value was lower
than 8, suggesting clinical remission,
but the patient was still reporting di-
minished interest, guilt feelings, feel-
ings of uselessness, and some degree
of anxiety. After the discontinuation of
the mood stabilizers and during the
course of ECT, the eating binges di-
minished, so the patient could lose
weight. This is important when consid-
ering the comorbidity with obesity and
its related risks, and because the weight
gain is associated with medication non-
compliance in many cases28. Kawachi29
also reported that along with the in-
creased risk of developing type II dia-
betes, hypertension, and coronary heart
disease (increasing the risk of death),
weight gain was also associated with a
poorer quality of life and stigmatiza-
tion. Headache and memory impair-
ment were side effects related to ECT.
The patient had already complained of
headache before the initiation of the
ECT course, and there was no worsen-
ing of the condition. The memory im-
pairment clearly developed in relation
to ECT and was rated as moderate.
CONCLUSION
The 3 cases reported here have
shown a good clinical response to ECT
after treatment resistance defined ac-
cording to the mentioned criteria. Al-
though obviously not statistically sig-
nificant, these case reports remind us
that ECT might be useful in the man-
agement of treatment-resistant patients
because of its effectiveness; it should
not be considered as a “last resort” in
the treatment of bipolar patients.
Remaining questions are to con-
sider whether ECT is associated with
a better or faster response than the new
pharmacological options such as the
anticonvulsants (valproate, lamotrigine,
gabapentin, and topiramate) and the
atypical antipsychotics (risperidone,
clozapine, olanzapine, and quetiapine).
This is an important issue that deserves
attention in the future, especially to
consider the cost-benefit relationship of
the treatment adopted. The faster, more
accessible, and cheaper treatment may
gain the advantage, principally in
countries where the economic issues of
the treatment of bipolar patients are
important. Another important issue that
needs to be addressed is the effective-
ness and tolerability of continuation
and maintenance of ECT among these
patients.
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A Eletroconvulsoterapia é uma al-
ternativa reconhecidamente eficaz no
tratamento dos transtornos do humor.
Embora vários estudos tenham confir-
mado a eficácia desta modalidade te-
rapêutica no tratamento da mania agu-
da, poucos estudos foram realizados
em pacientes maníacos resistentes à
farmacoterapia. Esses relatos de casos
descrevem resultados preliminares de
um projeto de pesquisa que tem por
objetivo avaliar a eficácia da Eletro-
convulsoterapia no tratamento de trans-
tornos bipolares resistentes.
MÉTODOS: Três pacientes com di-
agnóstico de mania (de acordo com os
critérios do DSM-IV), considerados re-
sistentes ao tratamento medicamentoso,
foram submetidos a 12 aplicações bila-
terais de Eletroconvulsoterapia. Antes
do tratamento e semanalmente, até o fi-
nal da série, foram avaliados com as es-
calas: Young Mania Rating Scale, Ha-
milton Rating Scale for Depression,
Brief Psychiatric Rating Scale e Clini-
cal Global Impressions-Bipolar Version.
RESULTADOS: Os três casos aqui
relatados apresentaram resposta satisfa-
tória à Eletroconvulsoterapia, e aspec-
tos individuais são discutidos.
CONCLUSÕES: Os resultados
iniciais sugerem que a eficácia da
Eletroconvulsoterapia no tratamento de
pacientes bipolares resistentes deve ser
melhor estudada.
DESCRITORES: Transtorno bi-
polar do humor. Mania. Trata-
mentos. Resistência à drogas. Eletro-
convulsoterapia.
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